Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2

European Heart Journal

Volumn 37, Issue 44, 2016, Pages 3347-3356

  Scavone, Mariangela ^a   Femia, Eti Alessandra ^a   Caroppo, Vera ^a   Cattaneo, Marco ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

Author keywords

Antiplatelet drugs; Aspirin; Myocardial infarction; P2Y12 receptor; Platelet aggregation; Thromboxane A2

Indexed keywords

4 (2 IODO 6 METHYLAMINO 9H PURIN 9 YL) 2 PHOSPHONOOXYBICYCLO[3.1.0]HEXANE 1 METHANOL; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CANGRELOR; CLOPIDOGREL; COLLAGEN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; THROMBOXANE B2; TICAGRELOR; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TREATMENT DURATION; CLINICAL TRIAL; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ASPIRIN; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2Y12; THROMBOXANE A2;

EID: 85015762581     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv551     Document Type: Article

References (30)

1. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010;121:171-179.
2. Leadbeater PD, Kirkby NS, Thomas S, Dhanji AR, Tucker AT, Milne GL, Mitchell JA, Warner TD. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost 2011;9:2050-2056.
3. Bhavaraju K, Georgakis A, Jin J, Gartner TK, Tomiyama Y, Nurden A, Nurden P, Kunapuli SP. Antagonism of P2Y12 reduces physiological thromboxane levels. Platelets 2010;21:604-609.
4. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011;9: 552-561.
5. Warner TD, Armstrong PC, Curzen NP, Mitchell JA. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart 2010;96:1693-1694.
6. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992;80:2787-2796.
7. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20:E101-E106.
8. Cattaneo M, Gachet C, Cazenave JP, Packham MA. Adenosine diphosphate(ADP) does not induce thromboxane A2 generation in human platelets. Blood 2002;99: 3868-3869; author reply 9-70.
9. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158-167.
10. Fontana G, Ware J, Cattaneo M. Haploinsufficiency of the platelet P2Y12 gene in a family with congenital bleeding diathesis. Haematologica 2009;94:581-584.
11. Lussana F, Di Marco F, Terraneo S, Parati M, Razzari C, Scavone M, Femia EA, Moro A, Centanni S, Cattaneo M. Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study. J Thromb Haemost 2015;13:136-141.
12. Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, Lussana F, Pugliano MT, Michelson AD. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost 2013;11:1183-1189.
13. Femia EA, Pugliano M, Podda G, Cattaneo M. Comparison of different procedures to prepare platelet-rich plasma for studies of platelet aggregation by light transmission aggregometry. Platelets 2012;23:7-10.
14. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007;92:694-7.
15. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317-327.
16. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372.
17. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011;117:2102-2112.
18. Lanza F, Cazenave JP, Beretz A, Sutter-Bay A, Kretz JG, Kieny R. Potentiation by adrenaline of human platelet activation and the inhibition by the alpha-adrenergic antagonist nicergoline of platelet adhesion, secretion and aggregation. Agents Actions 1986;18:586-595.
19. Lèon C, Vial C, Gachet C, Ohlmann P, Hechler B, Cazenave JP, Lecchi A, Cattaneo M. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost 1999;81: 775-781.
20. Brass LF, Woolkalis MJ, Manning DR. Interactions in platelets between G proteins and the agonists that stimulate phospholipase C and inhibit adenylyl cyclase. J Biolog Chem 1988;263:5348-5355.
21. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383.
22. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 2010;8:613-615.
23. Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD. Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 2011;9:2103-2105.
24. Kidson-Gerber G, Weaver J, Gemmell R, Prasan AM, Chong BH. Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. Heart Lung Circ 2010;19:234-242.
25. Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975;228: 1757-1765.
26. Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987;70:647-651.
27. Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK, Jacobson KA. Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol 2004;68: 1995-2002.
28. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
29. Paruchuri S, Tashimo H, Feng C, Maekawa A, XingW, Jiang Y, Kanaoka Y, Conley P, Boyce JA. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. JEM 2009;206:2543-2555.
30. Moscardó A, Santos MT, Fuset MP, Ruano M, Vallés J. Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction. Thromb Haemost 2011;105:663-669.